Screening for Barrett's esophagus

Reviews in Gastroenterological Disorders

Volumn 2, Issue SUPPL. 2, 2002, Pages

  Spechler, Stuart Jon ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Endoscopic screening; Surveillance

Indexed keywords

BARRETT ESOPHAGUS; CANCER MORTALITY; CANCER RISK; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE TRACT ENDOSCOPY; ESOPHAGUS CARCINOMA; EVIDENCE BASED MEDICINE; GASTROESOPHAGEAL REFLUX; REVIEW; SCREENING TEST;

ADENOCARCINOMA; BARRETT ESOPHAGUS; COST-BENEFIT ANALYSIS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; POPULATION SURVEILLANCE;

EID: 0036444094     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
2. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1973-1997. Bethesda, MD: National Cancer Institute, 2000.
3. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
4. Spechler SJ. Clinical practice. Barrett's esophagus. N Engl J Med. 2002;346:836-842.
5. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-215.
6. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333-338.
7. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol. 1999;94:2037-2042.
8. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical treatments for gastroesophageal reflux disease. Follow-up of a randomized controlled trial. JAMA. 2001;285:2331-2338.
9. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985;313:857-859.
10. Van der Veen AH, Dees J, Blankensteijn JD, van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut. 1989;30:14-18.
11. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med. 2001;111:33-37.
12. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol. 1994;89:670-680.
13. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg. 1993;105:383-388.
14. Peters JH, Clark GW, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813-822.
15. Corley DA, Levin TR, Habel LA, et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633-640.
16. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043-2053.
17. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective? Am J Gastroenterol. 2000;95:2086-2093.
18. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther. 2002;16:41-50.
19. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94:1434-1442.
20. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagitis. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 2002;97:1888-1895.
21. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002;287:1972-1981.
22. Hameeteman W, Tytgat G, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96:1249-1266.
23. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg. 1988;75:760-763.
24. Bonelli K. Barrett's esophagus: results of a multicentric survey. G.O.S.P.E. (Gruppo Operativo per lo Studio delle Precancerosi Esofagee). Endoscopy. 1993;25:652-654.
25. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut. 1991;32:1441-1446.
26. Iftikhar BV, James PD, Steele RJ, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 1992;33:1155-1158.